ProCE Banner Activity

Pilot Feasibility Study of BCL11A as Gene Therapy Target in Sickle Cell Disease

Slideset Download
Conference Coverage
Preliminary results from pilot feasibility study suggest that a gene therapy construct targeting BCL11A is safe, effectively induces HbF expression, and improves sickling signs and symptoms when delivered to patients with severe SCD.

Released: December 13, 2019

Expiration: December 11, 2020

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company